$-0.03
(Market cap
$6,077 Mln
Recently Viewed
Clear AllMarket cap
$6,077 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-5.8
Debt to Equity
0
Book Value
$10.8
EPS
$-1
Face value
--
Shares outstanding
115,413,392
CFO
$-272.77 Mln
EBITDA
$-337.05 Mln
Net Profit
$-327.81 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Terns Pharmaceuticals (TERN)
| 30.8 | 9.1 | 44.1 | 1,849.6 | 58.6 | 23.9 | -- |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Terns Pharmaceuticals (TERN)
| 629.2 | -14.5 | -36.2 | 44.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Terns Pharmaceuticals (TERN)
|
52.8 | 6,076.5 | 0.0 | -96.2 | -- | -14.2 | -- | 6.0 |
| 71.6 | 9,733.6 | 1,091.0 | 202.3 | 31.6 | 31.3 | 43.4 | 17.1 | |
| 65.1 | 8,216.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 46.6 | 11,658.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 90.7 | 11,852.6 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 68.8 | 8,209.1 | 1,396.6 | 316.9 | 59.8 | 153.6 | 27.1 | 161.7 | |
| 536.3 | 12,204.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.3 | |
| 513.8 | 14,867.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.4 | |
| 108.0 | 8,460.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.8 | |
| 340.1 | 9,538.9 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that... is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Read more
President & Head of Research & Development
Dr. Erin Quirk M.D.
President & Head of Research & Development
Dr. Erin Quirk M.D.
Headquarters
Foster City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Terns Pharmaceuticals Inc (TERN) is $52.84 (NASDAQ) as of 22-Apr-2026 10:38 EDT. Terns Pharmaceuticals Inc (TERN) has given a return of 58.58% in the last 3 years.
Since, TTM earnings of Terns Pharmaceuticals Inc (TERN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-39.05
|
3.73
|
|
2024
|
-4.99
|
1.28
|
|
2023
|
-5.11
|
1.80
|
|
2022
|
-6.07
|
1.32
|
|
2021
|
-3.24
|
1.01
|
The 52-week high and low of Terns Pharmaceuticals Inc (TERN) are Rs 53.19 and Rs 2.66 as of 22-Apr-2026.
Terns Pharmaceuticals Inc (TERN) has a market capitalisation of $ 6,077 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Terns Pharmaceuticals Inc (TERN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.